bioAffinity CEO to present at H.C. Wainwright conference Sept 14-16, 2026

bioAffinity Technologies, Inc.

President/CEO Maria Zannes will present corporate update and hold one-on-one investor meetings at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.
Presentation to feature CyPath Lung diagnostic test commercial adoption and technology platform advancements for diagnostics and therapeutics.
As of Sept 2, 2026, company had 600,736 common shares outstanding; aggregate market value ~$5.9M based on Nasdaq closing price.
Live and archived webcast of presentation available Sept 11 at https://bit.ly/BIAFPresentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.